http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Personalis to Participate in Upcoming Investor Conferences
-
Personalis to Announce Third Quarter 2020 Financial Results on November 5, 2020
-
Personalis to Participate in Immuno Series US Virtual Meeting
-
Personalis, Inc. to Present at IO Combinations 360˚
-
Personalis to Participate in Digital World CB & CDx Meeting
-
Personalis, Inc. (PSNL) Receives Contract Extension and New Task Order From the VA’s Million Veteran Program
-
Personalis Receives Contract Extension and New Task Order From the VA’s Million Veteran Program – Total Awarded to Date Now $175M
-
Personalis Strengthens Commercial Team with the Appointment of New Head of Population Genomics
-
Personalis to Participate in Upcoming Investor Conferences
-
Personalis to Participate at the Needham Virtual Cancer Diagnostics 1x1 Conference
-
Personalis Reports Second Quarter 2020 Financial Results
-
Personalis, Inc. Launches NeXT Liquid Biopsy™, A High-Performance, Exome-Wide Liquid Biopsy Platform
-
Personalis to Announce Second Quarter 2020 Financial Results on August 6, 2020
-
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Personalis Further Expands Leadership Team With Appointment of Leslie Grab, VP of Intellectual Property and John Lyle, VP of Assay Research and Development
-
Personalis Completes Sequencing 75,000th Whole Human Genome for VA MVP
-
Personalis Announces New Data to be Presented at AACR Virtual Scientific Meeting
-
Personalis to Participate in European Association for Cancer Research (EACR) 2020 Virtual Congress
-
Personalis to Present at the Precision Breast Cancer Summit
-
Personalis Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Personalis Announces a Partnership with Berry Genomics for China Expansion
-
Personalis Announces Scientific Collaboration with Sarepta Therapeutics on Immune Response to Precision Genetic Therapeutics
-
Personalis, Inc. Announces New Data to be Presented at ASCO Virtual Scientific Meeting
-
Personalis Reports First Quarter 2020 Financial Results
-
Personalis, Inc. Appoints Industry Veteran Stephen Moore as General Counsel
-
Personalis to Participate at Upcoming Investor Conferences
-
Personalis Announces Renewed Clinical Laboratory Accreditation from College of American Pathologists
-
Personalis to Announce First Quarter 2020 Financial Results on May 7, 2020
-
Indivumed, Personalis Partner to Enhance Genomic Sequencing Capabilities
-
Indivumed, Personalis Partner to Enhance Genomic Sequencing Capabilities
-
Personalis, Inc. Expands Genomics Portfolio Across Disease Areas With Launch of Pharma Research Solutions for Use in Early Drug Discovery and Preclinical Studies
-
Personalis to Participate at the 19th Annual Needham Virtual Healthcare Conference
-
Personalis Reports Fourth Quarter and Full Year 2019 Financial Results
-
Personalis to Announce Fourth Quarter and Full Year 2019 Financial Results on March 25, 2020
-
Personalis, Inc. to Present at Immuno-Oncology 360˚ Conference
-
Personalis, Inc. to Present at Biomarkers Series UK 2020 Conference
-
Personalis to Participate at the Cowen 40th Annual Health Care Conference
-
Advaxis and Personalis Announce Research Agreement to Deploy ImmunoID NeXT Platform in the ADXS-503 Clinical Program
-
Advaxis (ADXS) Gains 8% on Agreement with Personalis for ADXS-503 Trial
-
Advaxis and Personalis Announce Research Agreement to Deploy ImmunoID NeXT Platform in the ADXS-503 Clinical Program
-
Personalis, Inc. to Present at Precision Medicine World Conference 2020
-
Personalis, Inc. (PSNL) Announces the Launch of the NeXT Dx Test
-
Personalis, Inc. Announces the Launch of the NeXT Dx™ Test, a Comprehensive Genomic Cancer Profiling Test Enabling Advanced Composite Biomarkers for Cancer Treatment
-
Personalis, Inc. to Present at ESMO Immuno-Oncology Congress 2019
-
Personalis, Inc. to Present at NeoAg Summit US 2019
-
Personalis to Present at Upcoming Investor Conferences
-
Personalis, Inc. Announces Collaboration With Merck KGaA, Darmstadt, Germany, to Identify and Develop Novel Biomarkers for Cancer Therapies
-
Personalis, Inc. to Present New Data at the AACR Tumor Immunology and Immunotherapy Conference
-
Personalis Reports Third Quarter 2019 Financial Results
-
Personalis, Inc. Expands Oncology Portfolio With the Launch of Cancer Whole Genome Sequencing Services

